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Recently the Eurotransplant donor risk index (ET-DRI) was published, a model based on data from the Eurotransplant data-
base that can be used for risk indication of liver donors within the Eurotransplant region. Because outcome after liver trans-
plantation (LT) depends both on donor and recipient risk factors, a combined donor-recipient model (DRM) would give a
more complete picture of the overall risk involved. All liver transplants in adult recipients from January 1, 2008 to December
31, 2010 in the Eurotransplant region were included. Risk factors in donors and recipients for failure-free (retransplant free)
survival were analyzed in univariate and multivariate analyses. A simplified recipient risk index (sRRI) was constructed using
all available recipient factors. A total of 4466 liver transplants were analyzed. Median donor risk index and ET-DRI were
1.78 and 1.91, respectively. The ET-DRI was validated in this new cohort (P < 0.001; concordance index [c-index], 0.59).
After construction of a simplified recipient risk index of significant recipient factors, Cox regression analysis showed that the
combination ET-DRI and sRRI into a new DRM gave the highest predictive value (P < 0.001; c-index, 0.62). The combined
model of ET-DRI and sRRI gave a significant prediction of outcome after orthotopic LT in the Eurotransplant region, better
than the ET-DRI alone. This DRM has potential in comparing data in the literature and correcting for sickness/physical con-
dition of transplant recipients. It is a first step toward benchmarking of graft survival in the Eurotransplant region. Liver
Transpl 21:1486-1493, 2015. VC 2015 AASLD.
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Recently the Eurotransplant donor risk index (ET-DRI)
was published; it is a model that can be used to get an
indication of liver allograft quality for liver donors within
the Eurotransplant region.1 This model, based on the
donor risk index (DRI) by Feng et al.,2 uses 5 donor
factors (age, cause of death [COD], gamma-glutamyl
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transpeptidase [GGT], donation after cardiac death
[DCD], and split liver) and 3 transplant factors (alloca-
tion, rescue allocation, and cold ischemia time [CIT]) to
calculate the risk of failure-free survival (FFS) after liver
transplantation (LT) within the Eurotransplant region.
Obviously, the ET-DRI (or DRI) only represents the
impact of relevant donor and transplant risk factors on
outcome. In order to give a more complete picture of the
total risk of FFS after transplantation, recipient risk fac-
tors would also be needed.
In 2008, Schaubel et al.3 demonstrated the impact
of using liver allografts with a low, medium, or high
DRI for recipients in different Model for End-Stage
Liver Disease (MELD) categories,4 looking at survival
benefit.5 This study showed 2 interesting things:
median DRI tended to decrease as MELD at trans-
plant increased and patients with a MELD score  15
had a significant survival benefit from transplantation
(patients with MELD score  20 even had a significant
survival benefit when transplanted with any liver,
even with a high DRI).3 Altogether, it confirmed the
importance of donor-to-recipient matching in the con-
text of outcome after LT and survival benefit.
Several risk-indicating models combining donor,
transplant, and recipient characteristics have been
proposed previously, such as the survival outcomes
following liver transplantation (SOFT) score,6 donor
Model for End-Stage Liver Disease (D-MELD),7 or bal-
ance of risk (BAR).8 However, these models have only
very few variables (SOFT) or only donor age (D-MELD
and BAR) as the single donor factors and subsequently
lack important donor risk factors such as DCD or split
liver.9 Furthermore, these models are not validated in
a large data set, and there is no complete risk model
that is able to predict outcome for (European) deceased
donor liver allografts, taking all relevant donor, trans-
plant, and recipient characteristics into account.
This study aims to validate the ET-DRI and demon-
strate the combined positive effect of a comprehensive
predictive model consisting of donor risk factors (ET-
DRI) with basic recipient factors on outcome after LT.
PATIENTS AND METHODS
Data Selection
Data from all LTs performed from January 1, 2008 to
December 31, 2010 within the Eurotransplant region
were analyzed. All livers were recovered from deceased
donors. Livers transplanted into nonadult recipients
(<18 years; n 5 376) and transplantations performed
with donor liver allografts from outside Eurotrans-
plant (n 5 42) were excluded. Recipients with an
unknown MELD score at the time of transplantation
were excluded from the analysis (n 5 23).
The final analysis was performed with data of
4466 LTs.
Donor, transplant, recipient, and follow-up data
were obtained from the Eurotransplant Network
Information System and Eurotransplant Liver Follow-
up Registry, with consent of the Eurotransplant Liver
Intestine Advisory Committee. All data were made
anonymous for transplant center and country.
Statistical Analysis
The following factors were used in the statistical anal-
ysis. Donor factors were age, sex, height, weight, body
mass index, COD (trauma, cerebrovascular accident
[CVA], anoxia, and other), most recent GGT value,
serology of hepatitis B core antibody status and hepa-
titis C core antibody status, DCD, and split/partial
liver allografts. Transplant factors were allocation
(local, regional, and extraregional; definition as previ-
ously described1), rescue allocation (definition as pre-
viously described1), and CIT.
These factors were used to calculate the ET-DRI1
and DRI2 of all donors. In patients missing the latest
GGT (n 5 71; 1.6%) and CIT (n 5 896; 20%) data,
median values were imputed (GGT, 37 U/L; CIT, 9
hours). Because donor race is not registered in the
Eurotransplant database, all donors were regarded as
reference (Caucasian) when calculating the DRI.
Recipient factors were age, sex, etiology of liver dis-
ease (acute, cholestatic, alcoholic, malignant, meta-
bolic, hepatitis B, hepatitis C, other cause of cirrhosis,
or other/unknown cause), ABO compatibility, Euro-
transplant urgency status at transplant (high urgency
[HU] or not), repeated LT status, laboratory MELD
value, exception MELD value, and match MELD value.
(The match MELD is the MELD value used by Euro-
transplant in the liver allocation or on the liver match
list. This can be either laboratory MELD or exception
MELD, and the highest value applies.)
These factors were used to create a simplified recipient
risk index (sRRI), by adding the regression coefficients
obtained in a Cox regression model for FFS, using back-
ward selection with exit criterion of P > 0.05. For this
final model, the laboratory MELD value was used.
From the 4466 LTs included in this study, follow-up
was unknown in 87 (2%) patients; the remaining
4379 (98%) transplantations were used in the univari-
ate and multivariate survival analyses. The outcome
used in the analyses was FFS, defined as the period
between the dates of transplantation and retransplan-
tation or transplantation and recipient death, which-
ever occurred first. Most recent follow-up data were
used in the analyses.
For all analyses, a Wald P value of <0.05 was con-
sidered significant. Survival analyses were performed
using Kaplan-Meier survival models, and multivariate
analyses were performed using Cox regression mod-
els. All analyses were performed with SPSS, version
20.0 (IBM Corp., Armonk, NY), with the exception of
the calculation of the concordance index (c-index),
which was performed with R, version 2.12.0 (R Foun-
dation for Statistical Computing, Vienna, Austria).
RESULTS
A total of 4466 LTs were performed in adult recipients
in the Eurotransplant region during the study period.
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Demographics of donor and transplant characteristics
are shown in Table 1. Median donor age was 53 years,
and most frequent COD was by CVA (62%). Median
CIT was 9 hours, and 25% of all transplants were per-
formed with a rescue organ. Median DRI and ET-DRI
were 1.78 and 1.91, respectively. Demographics of
recipient characteristics are shown in Table 2. Median
recipient age was 55 years, and the most frequent eti-
ology of liver disease was alcoholic cirrhosis (24%),
followed by patients with a malignant etiology of liver
disease (21%). Patients were mainly transplanted
according to their laboratory MELD score (72%), with
a median laboratory MELD of 23 and match MELD of
25. Median posttransplantation follow-up was 3.3
years.
Distributions of DRI and ET-DRI among match and
laboratory MELD categories are shown in Fig. 1. The
patients in the laboratory and match MELD category
6-14 received the liver allografts with the highest
median ET-DRI.
Combined Donor and Recipient Risk
The log ET-DRI of all liver donors was analyzed in univari-
ate and multivariate analyses. In the Kaplan-Meier
survival analysis and Cox regression analysis, correcting
for recipient factors, the (log-)ET-DRI was highly signifi-
cant for FFS (log-rank test P< 0.001; Fig. 2).
The next step was to create a sRRI by analyzing all
recipient factors in a multivariate Cox regression anal-
ysis (Table 3). Two factors that were not significant
were excluded from the model (ABO compatibility, P 5
0.63; recipient HU status, P 5 0.26). After exclusion
of these 2 factors, the analysis was repeated to deter-
mine the coefficient of each factor. The complete
model was tested with both laboratory MELD and
match MELD categories. The highest c-index
TABLE 1. Donor and Transplant Characteristics of All
Liver Donors
Value (n 5 4466)
Donor factor
Age, years, median (range)* 53 (4-98)
<40, n (%) 908 (20)
40-49, n (%) 942 (21)
50-59, n (%) 1079 (24)
60-69, n (%) 863 (19)
70, n (%) 674 (15)
Sex, female, n (%) 2124 (48)
Height, cm, median (range)* 173 (107-200)






Last GGT, U/L, range (median)* 37 (0-1487)
HBcAb positive, n (%) 233 (5.2)
HCVAb positive, n (%) 46 (1)
DCD, n (%) 149 (3.3)
Transplant factor





Rescue allocation 1125 (25)
CIT, hours, median (range) 9 (0.3-37)
Risk index, median (range)
DRI 1.78 (0.8-3.5)
ET-DRI 1.91 (1.0-5.6)




(n 5 4466) P Value*
Age, years, median (range) 55 (18-77) 0.001
18-39, n (%) 475 (11)
40-49, n (%) 857 (19)
50-59, n (%) 1744 (39)
60-69, n (%) 1301 (29)
70, n (%) 89 (2)











Hepatitis B 152 (3.4)
Hepatitis C 495 (11)
Other cirrhosis 557 (12.5)
Other/unknown 245 (5.5)
ABO mismatch, n (%) 0.022
Identical 4139 (93)
Compatible 327 (7)
HU status 592 (13) <0.001
Retransplantation, n (%) <0.001
Yes 3868 (87)
No 598 (13)
MELD type allocation, n (%) Not
applicable
Laboratory MELD 3214 (72)




6-14, n (%) 794 (18)
15-24, n (%) 1309 (29)
25-34, n (%) 1573 (35)




6-14, n (%) 1610 (36)
15-24, n (%) 1249 (28)
25-34, n (%) 841 (19)
35, n (%) 766 (17)
*P value of univariate Kaplan-Meier analyses (n 5 4379).
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calculation was 0.606 for the sRRI with laboratory
MELD. Finally, this resulted in the following (log-)sRRI
(Table 3):
sRRI 5 exp[(0.066 if 40 years  age < 50 years OR
0.292 if 50 years  age < 60 years OR 0.455 if 60 years
 age < 70 years OR 0.572 if age  70 years) 1 (0.168
if male sex) 1 (0.520 if acute etiology OR 0.215 if cho-
lestatic etiology OR 0.154 if alcoholic OR 0.000 if
malignant OR 0.024 if hepatitis B OR 0.508 if hepatitis
C OR 0.059 if other cirrhosis OR 0.344 if other/
unknown) 1 (0.458 if repeated transplant) 1 (0.004 if
15  MELD < 25 OR 0.220 if 26  MELD < 35 OR
0.443 if MELD  35)].
The final step was to analyze the combined influ-
ence of ET-DRI and sRRI on outcome after LT, by
entering the logarithm of both indices in a Cox regres-
sion analysis (Table 3). Liver allografts with a high
ET-DRI tended to have been transplanted in a lower
Figure 1. Distribution of ET-DRI among match and lab MELD categories.
Figure 2. Kaplan-Meier survival analysis of ET-DRI categories.
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recipient risk, leading to the correlation between log
ET-DRI and log sRRI to be –0.088 (P < 0.001). Both
models were significantly associated with outcome (P
< 0.001), with a beta value of log ET-DRI 0.612 and
log sRRI 1.09 (c-index, 0.615), leading to the following
formula for the combined donor-recipient model
(DRM):
DRM ¼ expð0:614 ½log ET2DRI1 1:044 ½log sRRIÞ
The effect of this model is illustrated in Fig. 3, where
both models are divided into 3 categories (low/
medium/high; see Patients and Methods), based on
33rd percentiles in the survival analysis. The most
hazardous combination was high recipient risk index
(RRI) with high ET-DRI, leading to a hazard ratio of
2.82 (95% confidence interval, 2.27-3.50) as com-
pared to the reference (low RRI to low ET-DRI) in the
Cox regression analysis.
DISCUSSION
In this study, the effect of donor and pretransplant
recipient risk was demonstrated by combining a
donor risk model (ET-DRI)1 with a (new) recipient risk
model (sRRI) into a combined DRM. We think that
this new DRM is more complete than previous models
because it contains all relevant factors that have (sig-
nificant) impact on outcome after LT. Although a
recent study described the limited use of the DRI in
the Organ Procurement and Transplantation Network
(OPTN), the most important issues named are
TABLE 3. Results of Multivariate Cox Regression
Analysis of Factors in the sRRI
Recipient Factor Wald 95% CI
Age category 42.5
18-39 years Reference
40-49 years 0.445 0.88-1.30
50-59 years 10.4 1.12-1.60
60-69 years 23.7 1.31-1.89
70 years 10.9 1.26-2.49
Sex, male 9.83 1.07-1.32



















Figure 3. Kaplan-Meier survival analysis of combined donor (ET-DRI) and recipient (sRRI) risk.
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addressed by the new DRM model.10 Next to the crea-
tion of the DRM, the ET-DRI was validated in this
new cohort, confirming its correlation with outcome
after LT in the Eurotransplant region.
The sRRI that was created, as a first step toward the
DRM, used all available recipient factors currently
being collected in the Eurotransplant database. An
ideal RRI would consist of pretransplant recipient fac-
tors with significant impact on outcome after LT and
thereby (fully) indicating the status of this recipient at
the time of transplantation. In the current study, it is
shown that the pretransplant recipient risk has a very
high impact on the outcome after orthotopic LT, even
stronger than donor quality. This effect is shown in
the Kaplan-Meier survival curve (Fig. 3) and by the
weight of the sRRI in the DRM formula (weighing
1.044 sRRI versus 0.614 ET-DRI). The importance of
donor quality has the highest impact on patients in
the medium sRRI category as, for example, patients
with a medium sRRI transplanted with a high ET-DRI
liver allograft have comparable outcomes as compared
to high sRRI patients transplanted with a low ETDRI
liver allograft. Obviously, the transplant physician
and surgeon take these effects into account, but now
this DRM can be used to evaluate the combined effect
and as a tool to help select and quantify the risks of a
specific liver allograft for a specific recipient.
The discriminatory ability of the DRM was proven
by calculating the c-index, which was 0.62 in the cur-
rent database. This value is comparable to what has
been found in similar studies in liver, pancreas, or
kidney transplantation.1,11,12 A c-index above 0.6 is
regarded as acceptable, and a c-index above 0.7 is
regarded as good. However, if we look for examples in
other fields of medicine, a well-known model in breast
cancer screening, the Gail model of breast cancer risk
prediction,13 which has a c-index of 0.58 in a valida-
tion study,14 is (still) used worldwide and has been
cited over 2400 times. This indicates the clinical abil-
ity of a model with a c-index below 0.7. The fact that
the c-index of the ET-DRI remained stable as com-
pared to our previous study1 and that the c-index
increased after adding the sRRI (and thereby creating
the DRM) indicated the constant value of the model.
This fairly small increase in c-index is caused by the
fact that the recipient factors were already part of the
analysis in which the ET-DRI was validated. There-
fore, these factors had already been corrected for and
did not lead to a substantial increase in c-index. In
order to get a more realistic idea of the complete
DRM, this complete model should be validated in a
new data set. The difficulty with predicting survival in
LT is that the outcome of a single transplantation is
difficult to predict because it depends on many unpre-
dictable factors (such as the operation itself, infec-
tions, or other complications). The proposed model
would therefore be the best option currently available,
and in our opinion, it has an acceptable c-index to be
used.
The effect of donor and recipient combinations in
the OPTN was published by Schaubel et al.3 in 2008.
These findings were confirmed because donor quality
was also inversely matched to recipient status (eg,
low ET-DRI to high MELD and vice versa; Fig. 1).
This effect might be caused by the current practice
that high ET-DRI grafts are often declined for the
highest ranked patients on the waiting list and are
transplanted into the lower laboratory MELD recipi-
ents. Also in the case of a rescue allograft, the center
is able to select the recipient itself (which was the
case in this study cohort, but rules have changed
and this policy no longer applies) and centers could
have chosen lower match MELD recipients. In the
analysis, MELD was a significant predictor of post-
transplant survival (in univariate and multivariate
analysis) and an important part of the sRRI in con-
trast to the recently described conclusion in a sys-
tematic review of the literature by Klein et al.15 Next
to MELD, the importance of adequate matching and
allocation for recipients of repeat LT was recently
described by Biggins et al.16 This shows again that
repeat LT is an important risk factor that should be
part of any RRI.
One of the limitations of this study with regard to
the data collection is the high number of missing CITs
(20%). In order to calculate the ET-DRI and DRI, the
median value of 9 hours was used. For most trans-
plant centers, this would be more or less representa-
tive for the actual CIT. Also the impact of CIT on the
risk index is small (approximately 0.01 per additional
hour above 8 hours CIT), which makes it acceptable
in our perspective to not lose this high number of
transplants in the analysis. Another limitation is the
fact that this study was a retrospective cohort analy-
sis and that only the 6 recipient parameters collected
by Eurotransplant could be included. Nevertheless, 5
recipient factors significantly influenced outcome,
except for the factor “urgency.” Within the Eurotrans-
plant countries, transplant teams can request this HU
status for their recipient17 if this patient fulfills the
King’s College Criteria18 or Clichy criteria19 for acute
liver failure (ALF) or if a liver fails within 2 weeks after
the initial transplantation. Because ALF was one of
the subcategories in the factor “etiology of liver dis-
ease,” we hypothesize that the factor of HU was there-
fore of limited (not significant) impact in the
multivariate analysis. Also retransplantation is a fac-
tor that could have caused HU status not to be signifi-
cant because acute retransplantations within 2 weeks
after the initial transplant automatically receive HU
status. This group even has a higher risk than the pri-
mary ALF group.
This development of the DRM, as described in this
study, may ultimately lead toward the development of
a survival benefit–based model. In our opinion, there
should first be a complete DRM that could then be
used to calculate the survival benefit for patients on
the waiting list. The concept of survival benefit was
described a few years ago5 and was used by Schaubel
et al.20 to propose a new method for liver allocation.
In this article, they proposed a LT survival benefit
score based on 2 scores: a posttransplant survival
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model (c-index, 0.63) and a waiting list survival model
(c-index, 0.74). Although this is a very interesting and
statistically sound model, they used the “typical liver
donor” in their analyses (being a donor with reference
characteristics for categorical factors and approxi-
mately equal to the median for continuous factors).
Also, the question arises as to whether this situation
would be applicable for the Eurotransplant region
because allocation is arranged in a different way21
and because the donor population is different (refer-
ence donor from Scientific Registry of Transplant
Recipients is not equal to the Eurotransplant refer-
ence donor22).
Furthermore, there are several (ethical) aspects that
have to be addressed before it can be used in daily
practice.23 These data come from a large data set, and
one has to bear in mind that the prediction holds true
for a group of LT patients; but on a single-patient
level, the decision whether or not to accept that spe-
cific liver offer for that specific recipient should be
ultimately made by the treating physician.
Altogether, we think this DRM could be used to get
a more complete picture of the combined pretrans-
plant donor and recipient risks involved. The ET-DRI
and the newly developed sRRI were combined into 1
comprehensive model, DRM, that would be ideal for
comparing data in the literature and for interpretation
of outcome on, for example, a center level.
In conclusion, the ET-DRI is an indicator of donor
risk with significant predictive value of outcome after
LT in the Eurotransplant region and was validated in
this study. The combination of the ET-DRI with the
sRRI gives a more complete image of pretransplant
risks on outcomes after LT. This new DRM would be
helpful to understand and compare transplant out-
come data by correcting for donor and recipient case
mix and is a first step toward benchmarking of
patient and graft survival in the Eurotransplant
region.
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